Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
NCT05983432 · View on ClinicalTrials.gov ↗
Study Summary
The objective of this study is to evaluate the safety, tolerability, and efficacy of BL-B01D1 in patients with Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors.
Conditions Studied
Interventions
- DRUG BL-B01D1
Study Locations (20)
California
- Beverly Hills Cancer Center — Beverly Hills
- City of Hope Cancer Center — Duarte
- Chao Family Comprehensive Cancer Care and Ambulatory Care — Irvine
- Chao Family Comprehensive Cancer Center and Ambulatory Care — Irvine
- University of California Irvine Medical Center — Orange
- UCLA Santa Monica — Santa Monica
Florida
- Sylvester Comprehensive Cancer Center — Miami
- Sara Cannon Research Institute Lake Nona — Orlando
- Hematology - Oncology Associates of the Treasure Coast — Port Saint Lucie
Massachusetts
- Massachusetts General Hospital — Boston
- Dana-Farber Cancer Institute — Boston
Colorado
- University of Colorado Cancer Center — Aurora
Connecticut
- Yale University, Yale Cancer Center — New Haven
District of Columbia
- Georgetown University Medical Center — Washington D.C.
Illinois
- Northwestern University Feinberg School of Medicine — Chicago
Iowa
- University of Iowa Hospital and Clinics — Iowa City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 470 participants |
| Start Date | 2023-08-08 |
| Est. Completion | 2028-03-21 |
| Phase | Phase 1 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05983432
The ClinicalTrials.gov registry entry for NCT05983432 describes a study currently listed as recruiting. It is categorized as Phase 1, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 470 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SystImmune, which has 6 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 10 conditions, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention — of which BL-B01D1 is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT05983432 reports 20 study locations spanning 12 distinct geographic areas — top geographies include California, Florida, Massachusetts. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT05983432 about?
NCT05983432 is a clinical study titled "Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors". The objective of this study is to evaluate the safety, tolerability, and efficacy of BL-B01D1 in patients with Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors.
What is the current status of trial NCT05983432?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 470 participants. The study started on 2023-08-08. Estimated completion is 2028-03-21.
What conditions does trial NCT05983432 study?
This clinical trial studies the following conditions: Breast Cancer, Lung Cancer, Ovarian Cancer, Endometrial Cancer, Non Small Cell Lung Cancer. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT05983432?
The interventions under investigation include: BL-B01D1 (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT05983432?
This trial is sponsored by SystImmune, which has 6 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT05983432 being conducted?
This trial has 20 study locations across California, Colorado, Connecticut, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.